| 15.31 0.34 (2.27%) | 04-21 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 18.17 | 1-year : | 21.22 |
| Resists | First : | 15.56 | Second : | 18.17 |
| Pivot price | 13.3 |
|||
| Supports | First : | 12.79 | Second : | 11.09 |
| MAs | MA(5) : | 14.68 |
MA(20) : | 12.86 |
| MA(100) : | 15.58  |
MA(250) : | 17.78 |
|
| MACD | MACD : | 0.6 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 84.7 |
D(3) : | 78 |
| RSI | RSI(14): 74.5 |
|||
| 52-week | High : | 36.45 | Low : | 11.09 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ SLP ] has closed below upper band by 3.9%. Bollinger Bands are 23.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 15.37 - 15.43 | 15.43 - 15.49 |
| Low: | 14.76 - 14.83 | 14.83 - 14.9 |
| Close: | 15.19 - 15.3 | 15.3 - 15.41 |
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through four segments: Simulations Plus, Cognigen, DILIsym, and Lixoft. The company offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym, a quantitative systems pharmacology software; NAFLDsym; IPFsym; RENAsym; and MITOsym. In addition, the company provides Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as modeling and simulation products comprising MonolixSuite and PKPlus. Further, it provides population modeling and simulation contract research services; training and consulting services designed to accelerate pharmacometrics studies; and clinical-pharmacology-based consulting services in support of regulatory submissions. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
Wed, 22 Apr 2026
Simulations Plus partners with Lonza and FDA on drug formulation research - Investing.com India
Tue, 21 Apr 2026
Simulations Plus (SLP) Partners with FDA and Lonza for Drug Perf - GuruFocus
Mon, 20 Apr 2026
Simulations Plus Inc Announces Completion of 2026 Spring School Global Training Initiative - marketscreener.com
Mon, 20 Apr 2026
Simulations Plus Expands Global Access to Model-Informed Drug Development Training Through Its 2026 Spring School - Business Wire
Sun, 19 Apr 2026
Here’s Simulations Plus Inc (SLP)’s Vision for AI in Drug Development - Yahoo Finance
Thu, 16 Apr 2026
John Anthony Dibella II Sells 1,000 Shares of Simulations Plus (NASDAQ:SLP) Stock - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Healthcare Information Services
|
|
| Shares Out | 20 (M) |
| Shares Float | 17 (M) |
| Held by Insiders | 17.2 (%) |
| Held by Institutions | 85.5 (%) |
| Shares Short | 1,200 (K) |
| Shares Short P.Month | 1,330 (K) |
| EPS | -3.12 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.61 |
| Profit Margin | -78 % |
| Operating Margin | 23.1 % |
| Return on Assets (ttm) | 3.8 % |
| Return on Equity (ttm) | -38.9 % |
| Qtrly Rev. Growth | 8.3 % |
| Gross Profit (p.s.) | 2.46 |
| Sales Per Share | 3.98 |
| EBITDA (p.s.) | 0.69 |
| Qtrly Earnings Growth | 46.7 % |
| Operating Cash Flow | 24 (M) |
| Levered Free Cash Flow | 17 (M) |
| PE Ratio | -4.91 |
| PEG Ratio | 9.8 |
| Price to Book value | 2.31 |
| Price to Sales | 3.84 |
| Price to Cash Flow | 12.69 |
| Dividend | 0.05 |
| Forward Dividend | 0 |
| Dividend Yield | 0.3% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|